SCHEMBL604822

SCHEMBL604822

CC(c1ccccc1)N(C(=O)c1ccccc1C(=O)O)C(C)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 4/20 0.50
ALOX15 P16050 2/20 0.50
ALDH1A1 P00352 2/20 0.50
ALOX5 P09917 1/20 0.47
KDM4E B2RXH2 1/20 0.45
TAAR1 Q96RJ0 1/20 0.45
NR1I2 O75469 1/20 0.45
MYC P01106 3/20 0.43
NR4A1 P22736 1/20 0.43
MTOR P42345 1/20 0.42
MAPT P10636 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
AKR1C3 P42330 1/20 0.41
SRC P12931 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3068504 1.00 TRPM8 (0.50) TRPM8ALOX15ALDH1A1ALOX5KDM4E
SCHEMBL3062350 1.00 TRPM8 (0.50) TRPM8ALOX15ALDH1A1ALOX5KDM4E
SCHEMBL6457702 0.86 TRPM8 (0.55) TRPM8ALDH1A1ALOX5KDM4ENR1I2
SCHEMBL5805578 0.84 ALOX5 (0.59) TRPM8ALOX15ALDH1A1ALOX5MYC
SCHEMBL21891698 0.83 ALDH1A1 (0.56) ALOX15ALDH1A1KDM4EMYCNR4A1
SCHEMBL28566234 0.79 ALOX5 (0.47) TRPM8ALOX15ALDH1A1ALOX5KDM4E
SCHEMBL29980356 0.79 ALOX5 (0.47) TRPM8ALOX15ALDH1A1ALOX5KDM4E
SCHEMBL28549723 0.79 ALOX5 (0.47) TRPM8ALOX15ALDH1A1ALOX5KDM4E
Phthalic Acid SCHEMBL28418540 0.76 ALDH1A1 (0.78) ALOX15ALDH1A1KDM4EMYCNR4A1
Phthalic Acid SCHEMBL28043206 0.75 ALDH1A1 (0.61) ALOX15ALDH1A1KDM4ETAAR1MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12551465-B2 Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition CELLTRION INC. (KR) 2026-02-17 US claimed
US-20230190708-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION CELLTRION, INC. (KR) 2023-06-22 US claimed
EP-4140482-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION Celltrion, Inc. (KR) 2023-03-01 EP claimed
WO-2021215852-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION (주)셀트리온 (KR) 2021-10-28 WO claimed
EP-2260029-B1 PREPARATION OF MORPHOLINE DERIVATIVES SANDOZ AG (CH) 2014-10-01 EP claimed
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2012-02-16 US claimed
US-20110009629-A1 PREPARATION OF MORPHOLINE DERIVATIVES SANDOZ AG (CH) 2011-01-13 US claimed
EP-1981831-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF Vaidya, Niteen A. (US) 2008-10-22 EP claimed
WO-2007092264-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2007-08-16 WO claimed
US-20070185346-A1 Kit for automated resolving agent selection and method thereof VAIDYA NITEEN A 2007-08-09 US claimed
US-12551465-B2 Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition CELLTRION INC. (KR) 2026-02-17 US disclosed
CN-115297858-B Pharmaceutical composition for treating hypertrophic cardiomyopathy and treatment method using the same 赛特瑞恩股份有限公司 2024-08-13 CN disclosed
US-20230190708-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION CELLTRION, INC. (KR) 2023-06-22 US disclosed
EP-4140482-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION Celltrion, Inc. (KR) 2023-03-01 EP disclosed
CN-115297858-A Pharmaceutical composition for treating hypertrophic cardiomyopathy and treatment method using same 赛特瑞恩股份有限公司 2022-11-04 CN disclosed
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2012-02-16 US disclosed
US-20110009629-A1 PREPARATION OF MORPHOLINE DERIVATIVES SANDOZ AG (CH) 2011-01-13 US disclosed
EP-1981831-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF Vaidya, Niteen A. (US) 2008-10-22 EP disclosed
WO-2007092264-A2 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF VAIDYA NITEEN A (US) 2007-08-16 WO disclosed
US-20070185346-A1 Kit for automated resolving agent selection and method thereof VAIDYA NITEEN A 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009629-A1 PREPARATION OF MORPHOLINE DERIVATIVES OPRK1, TACR1, CMA1 TRPM8 400/4885ALOX15 926/4885ALDH1A1 1063/4885
US-12551465-B2 Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition ME2, TNNT2, TNNC1 TRPM8 788/4885ALOX15 544/4885ALDH1A1 440/4885
US-20120041225-A1 KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF ACKR3, KIT, C3AR1 TRPM8 3562/4885ALOX15 703/4885ALDH1A1 1235/4885
US-20230190708-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION ATP2A2, CPT1B, TNNT2 TRPM8 726/4885ALOX15 1767/4885ALDH1A1 1793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.